$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023065678 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue		$674.0K
YoY Change		0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.936M	$2.644M
YoY Change	-45.06%	-9.2%
% of Gross Profit
Research & Development	$957.0K	$1.821M
YoY Change	-82.1%	-80.16%
% of Gross Profit
Depreciation & Amortization	$50.00K	$52.00K
YoY Change	233.33%	246.67%
% of Gross Profit
Operating Expenses	$2.893M	$4.465M
YoY Change	-67.39%	-63.07%
Operating Profit	-$2.893M	-$3.791M
YoY Change	-64.67%	-66.8%
Interest Expense	$826.0K	$2.478M
YoY Change	-20.27%	608.0%
% of Operating Profit
Other Income/Expense, Net	$435.0K	$2.478M
YoY Change	-58.01%
Pretax Income	-$3.284M	-$1.313M
YoY Change	-54.09%	-88.14%
Income Tax
% Of Pretax Income
Net Earnings	-$3.222M	-$1.194M
YoY Change	-55.58%	-89.21%
Net Earnings / Revenue		-177.15%
Basic Earnings Per Share	$0.08	$0.03
Diluted Earnings Per Share	$0.08	$0.03
COMMON SHARES
Basic Shares Outstanding	40.28M shares	40.03M shares
Diluted Shares Outstanding	40.45M shares	40.23M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$175.0M	$7.101M
YoY Change	365.49%	-80.39%
Cash & Equivalents	$5.468M	$6.767M
Short-Term Investments	$169.6M	$334.0K
Other Short-Term Assets	$700.0K	$769.0K
YoY Change	12.36%	-19.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$175.7M	$151.0M
YoY Change	9.7%	11.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$923.0K	$945.0K
YoY Change	72.52%	120.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$53.50M	$3.531M
YoY Change	1880.01%	-86.36%
Other Assets	$0.00	$26.00K
YoY Change	-100.0%	13.04%
Total Long-Term Assets	$55.19M	$5.344M
YoY Change	1193.97%	-80.51%
TOTAL ASSETS
Total Short-Term Assets	$175.7M	$151.0M
Total Long-Term Assets	$55.19M	$5.344M
Total Assets	$230.9M	$156.3M
YoY Change	40.41%	-3.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.600M	$828.0K
YoY Change	-38.17%	-76.21%
Accrued Expenses	$300.0K	$236.0K
YoY Change	31.58%	1.29%
Deferred Revenue
YoY Change
Short-Term Debt	$75.36M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$78.18M	$1.067M
YoY Change	1098.08%	-83.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.500M	$4.592M
YoY Change	-5.56%	61.92%
Total Long-Term Liabilities	$4.488M	$4.592M
YoY Change	-5.81%	61.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$78.18M	$1.067M
Total Long-Term Liabilities	$4.488M	$4.592M
Total Liabilities	$82.66M	$5.659M
YoY Change	632.18%	-38.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$170.9M	-$167.7M
YoY Change	10.58%	13.69%
Common Stock	$320.0M	$484.0K
YoY Change	67990.21%	4.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$149.1M	$151.5M
YoY Change
Total Liabilities & Shareholders Equity	$230.9M	$156.3M
YoY Change	40.41%	-3.68%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.222M	-$1.194M
YoY Change	-55.58%	-89.21%
Depreciation, Depletion And Amortization	$50.00K	$52.00K
YoY Change	233.33%	246.67%
Cash From Operating Activities	-$700.0K	-$2.634M
YoY Change	-68.76%	-68.98%
INVESTING ACTIVITIES
Capital Expenditures	$30.00K	$20.00K
YoY Change	-124.79%	-200.0%
Acquisitions
YoY Change
Other Investing Activities	-$75.09M	-$14.69M
YoY Change	-5662.22%	-241.48%
Cash From Investing Activities	-$75.13M	-$14.71M
YoY Change	-6213.1%	-241.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	74.55M	0.000
YoY Change	1628.5%	-100.0%
NET CHANGE
Cash From Operating Activities	-700.0K	-2.634M
Cash From Investing Activities	-75.13M	-14.71M
Cash From Financing Activities	74.55M	0.000
Net Change In Cash	-1.280M	-17.34M
YoY Change	-138.78%	-1026.5%
FREE CASH FLOW
Cash From Operating Activities	-$700.0K	-$2.634M
Capital Expenditures	$30.00K	$20.00K
Free Cash Flow	-$730.0K	-$2.654M
YoY Change	-65.57%	-68.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40144725	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
CY2022Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	50000	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35813
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0376008
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Third Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
	dei	Local Phone Number LocalPhoneNumber	844-967-2633
	dei	City Area Code CityAreaCode	844
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.012
	dei	Trading Symbol TradingSymbol	ORMP
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40275688	shares
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6767000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	40464000	usd
CY2023Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	142491000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	111513000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	943000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	769000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1389000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	150970000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	157109000	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2023Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	3524000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	2700000	usd
CY2023Q2	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	26000	usd
CY2022Q4	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	24000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	945000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	815000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	842000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	5344000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4533000	usd
CY2023Q2	us-gaap	Assets Assets	156314000	usd
CY2022Q4	us-gaap	Assets Assets	161642000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	828000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4158000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1340000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	3000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	236000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1067000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5746000	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	27000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	21000	usd
CY2023Q2	ormp	Provision For Uncertain Tax Position ProvisionForUncertainTaxPosition	11000	usd
CY2022Q4	ormp	Provision For Uncertain Tax Position ProvisionForUncertainTaxPosition	11000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	488000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2023Q2	us-gaap	Other Liabilities OtherLiabilities	66000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	61000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4592000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4740000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40219396	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40219396	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39563888	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39563888	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	484000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	476000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	318732000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	314417000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167670000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163081000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	151546000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	151812000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-891000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-656000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	150655000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	156314000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161642000	usd
	us-gaap	Revenues Revenues	1340000	usd
	us-gaap	Revenues Revenues	1340000	usd
CY2023Q2	us-gaap	Revenues Revenues	674000	usd
CY2022Q2	us-gaap	Revenues Revenues	674000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6248000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15015000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1821000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9179000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	376000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	970000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	192000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	380000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3715000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8024000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2452000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2532000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8999000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22669000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3791000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11417000	usd
	ormp	Financialincomes FINANCIALINCOMES	4075000	usd
	ormp	Financialincomes FINANCIALINCOMES	894000	usd
CY2023Q2	ormp	Financialincomes FINANCIALINCOMES	2478000	usd
CY2022Q2	ormp	Financialincomes FINANCIALINCOMES	350000	usd
	us-gaap	Profit Loss ProfitLoss	-4924000	usd
	us-gaap	Profit Loss ProfitLoss	-21775000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1313000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-11067000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-335000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-817000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-119000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-534000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4589000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20958000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1194000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10533000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.54
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40144725	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38732636	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40225594	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38795318	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2430000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1893000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	100000	usd
	us-gaap	Profit Loss ProfitLoss	-4924000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	150655000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166610000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2968000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	5911000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-677000	usd
	us-gaap	Profit Loss ProfitLoss	-21775000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	153037000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	150148000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1770000	usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	50000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1313000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	150655000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	162223000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-1000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1882000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-11067000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	153037000	usd
	us-gaap	Profit Loss ProfitLoss	-4924000	usd
	us-gaap	Profit Loss ProfitLoss	-21775000	usd
	us-gaap	Depreciation Depreciation	89000	usd
	us-gaap	Depreciation Depreciation	26000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	457000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	319000	usd
	ormp	Changes At Fair Value Of Investments ChangesAtFairValueOfInvestments	820000	usd
	ormp	Changes At Fair Value Of Investments ChangesAtFairValueOfInvestments	-375000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1993000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5911000	usd
	ormp	Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement GainOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	2000	usd
	ormp	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	620000	usd
	ormp	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	699000	usd
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	3328000	usd
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	1054000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	25000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	99000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1340000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1340000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	6000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1000	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	5000	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-38000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8183000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17615000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89919000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	107000000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	59500000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	121000000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	2725000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	3786000	usd
	ormp	Proceeds From Funds In Respect Of Employee Rights Upon Retirement ProceedsFromFundsInRespectOfEmployeeRightsUponRetirement	-3000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27913000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17722000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2430000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2968000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	677000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2430000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2291000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-31000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33697000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2436000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40464000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27456000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6767000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29892000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2866000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	739000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	678000	usd
CY2023Q2	us-gaap	Common Unit Issued CommonUnitIssued	1890000	shares
	ormp	Shares Issued And Outstanding Percentage SharesIssuedAndOutstandingPercentage	0.63	pure
	ormp	Aggregate Face Amount AggregateFaceAmount	99550000	usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3694057	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3470361	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	4026508	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3477121	shares
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue recognition</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><i>HTIT</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On November 30, 2015, the Company entered into a Technology License Agreement (the “TLA”), with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">As of June 30, 2023, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through the balance sheet date. Through June 30, 2023, the Company recognized revenue associated with this agreement in the aggregate amount of $20,382, of which $1,340 was recognized in the six month period ended June 30, 2023, and deferred the remaining amount of $2,000, which is presented as long-term deferred revenues on the condensed consolidated balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><i>Medicox</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On November 13, 2022, the Company entered into a distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”). The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. For further details, see note 3a.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under ASC 606, the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company identified a performance obligation in the Medicox License Agreement to stand-ready and provide Medicox with support in its commercialization efforts in the Republic of Korea. This performance obligation includes a non-distinct distribution license for ORMD-0801, which the Company views a predominant item in the combined performance obligation. The Company concluded that the license is not distinct, as no party other than the Company is capable of providing related services to Medicox, and both the license and related services are necessary for the customer to obtain a regulatory approval in the Republic of Korea. In addition, the agreement covers the terms of future manufacturing services, that are contingent on the completion and success of the commercialization efforts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company in fiscal year 2022 and is presented under long-term deferred revenues as of June 30, 2023. It also contains variable consideration of contractual milestone payments and sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of June 30, 2023, this support has not commenced, and no revenue was recognized from the Medicox License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized at a later stage. The Company notes that its Phase 3 trial did not meet its primary and secondary endpoints. If Medicox chooses to terminate the agreement as a result of the outcome of the applicable Phase 3 trials, the Company expects to accelerate revenue recognition and recognize it at such time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-size: 9pt"> </span></p>
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	20382000	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	1340000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2000000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2000000	usd
CY2022Q4	ormp	Right Terminate Years RightTerminateYears	P10Y
CY2022Q4	us-gaap	Advances For Gas Exploration Development And Production Amount AdvancesForGasExplorationDevelopmentAndProductionAmount	15000000	usd
CY2022Q4	ormp	Development Received Amount DevelopmentReceivedAmount	2000000	usd
CY2022Q4	ormp	Royalties Percentage RoyaltiesPercentage	0.15	pure
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2548000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	96000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	334000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	352000	usd
CY2023Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	99000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	85000	usd
CY2023Q2	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	510000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	3306000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	943000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2023Q2	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2023Q2	us-gaap	Other Investments OtherInvestments	1000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	510000	usd
	ormp	Gross Unrealized Gainslosses GrossUnrealizedGainslosses	-10000	usd
CY2023Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	500000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3306000	usd
CY2022	ormp	Gross Unrealized Gainslosses GrossUnrealizedGainslosses	-82000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	3224000	usd
CY2022Q3	ormp	Aggregate Purchase Prices AggregatePurchasePrices	2700000	usd
CY2022Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.05	pure
	us-gaap	Dividend Income Equity Securities Operating DividendIncomeEquitySecuritiesOperating	824000	usd
CY2021Q3	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	100000000	usd
CY2021Q3	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.03	pure
CY2023Q2	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	1971447	shares
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	26253000	usd
CY2023Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	26253000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	842000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	236000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	488000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	724000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	894000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	138000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	291000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	276000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	291000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	217000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	228000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	118000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	124000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	759000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	944000	usd
CY2023Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	35000	usd
CY2023Q2	ormp	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	724000	usd
CY2022Q4	ormp	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	894000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	190000	usd
CY2022Q4	us-gaap	Sponsor Fees SponsorFees	88023000	ils
CY2022Q4	us-gaap	Sponsor Fees SponsorFees	24000	usd
CY2022Q4	us-gaap	Salaries And Wages SalariesAndWages	46901000	ils
CY2022Q4	us-gaap	Salaries And Wages SalariesAndWages	13000	usd
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	1
CY2023Q2	us-gaap	Liabilities Subject To Compromise Early Contract Termination Fees LiabilitiesSubjectToCompromiseEarlyContractTerminationFees	3413000	usd
	us-gaap	Investment Company Expense After Reduction Of Fee Waiver And Reimbursement InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement	1000000	usd
CY2023Q2	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.15	pure
	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.03	pure
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38732636	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38795318	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40225594	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	ormp	Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement GainOnAmountsFundedInRespectOfEmployeeRightsUponRetirement		usd
	ormp	Proceeds From Funds In Respect Of Employee Rights Upon Retirement ProceedsFromFundsInRespectOfEmployeeRightsUponRetirement		usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309

Files In Submission

Name	View Source	Status
0001213900-23-065678-index-headers.html	Edgar Link	pending
0001213900-23-065678-index.html	Edgar Link	pending
0001213900-23-065678.txt	Edgar Link	pending
0001213900-23-065678-xbrl.zip	Edgar Link	pending
f10q0623ex10-1_oramedphar.htm	Edgar Link	pending
f10q0623ex2-2_oramedphar.htm	Edgar Link	pending
f10q0623ex31-1_oramedphar.htm	Edgar Link	pending
f10q0623ex31-2_oramedphar.htm	Edgar Link	pending
f10q0623ex32-1_oramedphar.htm	Edgar Link	pending
f10q0623ex32-2_oramedphar.htm	Edgar Link	pending
f10q0623_oramedphar.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ormp-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
ormp-20230630_cal.xml	Edgar Link	unprocessable
ormp-20230630_def.xml	Edgar Link	unprocessable
ormp-20230630_lab.xml	Edgar Link	unprocessable
ormp-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_oramedphar_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2023 Q3 Form 10-Q Financial Statement

#000121390023065678 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2023 Q3 Form 10-Q Financial Statement

#000121390023065678 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp